PDCD1LG2 and carcinoma of esophagus: Considering that drugs targeting the PD-1 pathway are being intensively developed and tested in clinical trials for various human cancers, PD-L1 and PD-L2 expression in oesophageal cancer may serve as a predictive biomarker, and may be used for patient selection in clinical trials of such drugs.